Newsletter Sign Up

StopAfib.org

Newsletter Signup
Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference. Aug 4-6, 2017, in Dallas, TX
Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference. Aug 4-6, 2017, in Dallas, TX

The reMARQable Trial Will Study the nMARQ Multielectrode Irrigated Catheter for Treating Paroxysmal Atrial Fibrillation

The reMARQable trial compares the Biosense Webster nMARQ multielectrode catheters to the ThermoCool irrigated catheter for treatment of paroxysmal afib

By Mellanie True Hills and Melissa Moss

June 26, 2014

  • Summary:  The reMARQable trial will study the nMARQ multielectrode irrigated catheter for treatment of paroxysmal atrial fibrillation
  • Reading time: 1–2 minutes

The reMARQable trial, sponsored by Biosense Webster, is studying the nMARQ system employing multiple electrodes on an irrigated catheter. There are two formats — a circular catheter with ten electrodes and a crescent catheter with seven electrodes.

The trial, in patients with symptomatic paroxysmal atrial fibrillation, will compare the nMARQ multi-electrode irrigated catheter to the currently-approved Biosense Webster ThermoCool irrigated catheter.

To learn more about the nMARQ catheter and the reMARQable study, including who is eligible and what centers are participating, see:

Back to News

Last Modified June 26, 2014

Get Started Learning About Atrial Fibrillation

Afib Community

Blog Forum

Locate Help

Afib services near you

USA Locations International Locations List Your Afib Services

We comply with the HONcode standard for trustworthy health information: verify here.

Newsletter Sign Up